

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8222)

DISCLOSEABLE TRANSACTION

in respect of

the acquisition of approximately 17.86% interest in Tongrui Holdings Limited

On 17 September 2007 after trading hours, Turrence Limited (an indirect wholly-owned subsidiary of the Company) entered into the Agreement with the Warrantor and Furui, which is and the ultimate beneficial owners of which are, to the best of the Directors' knowledge, information and belief having made all reasonable enquiries, third parties independent of the Company and its connected persons (as defined in the GEM Listing Rules), whereby Turrence Limited agreed to acquire the Sale Shares at an aggregate consideration of HK\$150,000,000 in cash.

The Acquisition contemplated in the Agreement constitutes a discloseable transaction for the Company under Chapter 19 of the GEM Listing Rules. A circular containing further information about the Acquisition will be despatched to the shareholders of the Company as soon as practicable.

THE AGREEMENT

Date: 17 September 2007

- Parties:
- (i) Turrence Limited
 - (ii) Furui
 - (iii) the Warrantor

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, Furui and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the GEM Listing Rules).

ASSETS TO BE ACQUIRED

The Sale Shares (being 2,491.7 Tongrui Shares) representing approximately 17.86% of the issued shares of Tongrui. The Group does not have any shareholding in Tongrui prior to the Acquisition. The Group has no present intention to acquire any further interest in Tongrui after completion of the Acquisition.

CONSIDERATION

The consideration for the Acquisition of the Sale Shares is HK\$150,000,000 in aggregate, which will be settled in cash on completion of the Acquisition.

The consideration will be satisfied by the Group's internal resources.

CONDITIONS

Completion of the Acquisition is conditional upon the following:

- (i) execution of a shareholders' agreement by all relevant parties; and
- (ii) until completion of the Acquisition, there will be no material adverse change to the warranties that will render them seriously untrue.

In the event that the above conditions are not fulfilled at or before 5:00 p.m. on 31 October 2007 (or such later date as may be agreed by the respective parties in writing under the Agreement), neither party under the Agreement will be obliged to proceed with the completion of the Acquisition, and neither party under the Agreement will have any claim against the other except in respect of any antecedent breach under the Agreement.

INFORMATION ON TONGRUI, FURUI AND THE WARRANTOR

Tongrui is a company incorporated under the laws of the B.V.I. The principal activity of Tongrui is investment holding. Tongrui owns a 100% interest in Jet Bright International Holdings Limited 捷輝國際集團有限公司 (“**Jet Bright**”), a company incorporated under the laws of Hong Kong, which controls a 100% interest in Wuxi Ruinian. The principal activity of Jet Bright is investment holding in Wuxi Ruinian. Wuxi Ruinian is principally engaged in the manufacture and marketing of nutraceutical products in the PRC. Wuxi Ruinian’s main products include amino acid tablets, royal jelly products, protein powder and collagen products. Wuxi Ruinian is also engaged in nutraceutical-related technical research and development activities.

Upon completion of the Acquisition, the Group will have one seat in the board of directors of Tongrui. There will not be any change in the board composition of Jet Bright and Wuxi Ruinian at the time the Acquisition is completed.

Furui is a company incorporated under the laws of the B.V.I. The principal activity of Furui is investment holding. Prior to the Acquisition, Furui was interested in approximately 96.88% of the issued share capital of Tongrui.

The Warrantor is the ultimate beneficial owner of Furui.

The Group has taken into account the following factors in determining the consideration for the Acquisition, which was arrived at after arm's length negotiations between the parties: (i) the economic benefits of the transaction to the Group; (ii) the future prospects of the business of Tongrui; (iii) the synergistic effects and strategic value of Tongrui and its subsidiaries on the future development of the Group; and (iv) the potential business opportunities that can be provided to the Group.

Based on the accounts of Wuxi Ruinian as at 31 December 2006, the audited net asset value of Wuxi Ruinian was approximately RMB247 million (approximately HK\$255 million). The audited net profits before taxation and extraordinary items of Wuxi Ruinian for the two years ended 31 December 2005 and 2006 were approximately RMB71 million (approximately HK\$73 million) and approximately RMB43 million (approximately HK\$44 million) respectively. The respective audited net profits after taxation and extraordinary items of Wuxi Ruinian for the two years ended 31 December 2005 and 2006 were approximately RMB71 million (approximately HK\$73 million) and approximately RMB37 million (approximately HK\$38 million). The above accounts were prepared under the PRC GAAP.

The above figures are based on Wuxi Ruinian's auditor's report for 2006.

There was no prior transaction or relationship between the Group and Tongrui and its ultimate beneficial owner(s) that requires aggregation under Rule 19.22 of the GEM Listing Rules.

REASONS FOR ENTERING INTO THE ACQUISITION

Tongrui, through its direct wholly-owned subsidiary, is currently interested in the entire issued share capital of Wuxi Ruinian, a company which focuses on the area of nutraceutical business. Wuxi Ruinian intends to expand its business in the PRC and Hong Kong. Acquisition of Tongrui will enable the Group to expand further the geographical coverage, product portfolio, manufacturing capability and customer base of its nutraceutical business.

Following completion of the Acquisition, the investment in Tongrui will be classified as a long-term investment in the consolidated balance sheet of the Group.

GENERAL

The Directors (including the Independent Non-executive Directors) considered that the Agreement is entered into on normal commercial terms in the ordinary and usual course of business of the Group and that the terms of the Agreement are fair and reasonable and in the best interests of the Group so far as the interests of the shareholders of the Company are concerned.

The Company acts as an investment holding company. Its subsidiaries are principally engaged in research and development, manufacturing, commercialization, marketing and selling of environmental and human health products, as well as investment in various financial and investment products.

The Acquisition contemplated in the Agreement constitutes a discloseable transaction for the Company under Chapter 19 of the GEM Listing Rules. A circular containing further information about the Acquisition will be despatched to the shareholders of the Company as soon as practicable.

DEFINITIONS

"Acquisition"	the acquisition of the Sale Shares as contemplated in the Agreement
"Agreement"	the agreement for sale and purchase dated 17 September 2007 entered into after trading hours on 17 September 2007 between Turrence Limited, Furui and the Warrantor, relating to the Acquisition
"B.V.I."	British Virgin Islands
"Board"	the board of directors of the Company
"Company"	CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability
"Directors"	the directors of the Company
"Furui"	Furui Investments Limited 福瑞投資有限公司, a company incorporated in the B.V.I. with limited liability
"GAAP"	generally accepted accounting principles
"GEM Listing Rules"	the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited
"Group"	the Company and its subsidiaries
"HK\$"	the lawful currency of the Hong Kong Special Administrative Region of the PRC
"Hong Kong"	Hong Kong Special Administrative Region of the PRC
"PRC"	the People's Republic of China
"RMB"	Renminbi, the lawful currency of the PRC
"Sale Shares"	2,491.7 Tongrui Shares, representing approximately 17.86% of the issued shares of Tongrui

"Tongrui"	Tongrui Holdings Limited 同瑞控股有限公司, a company incorporated in the B.V.I. with limited liability
"Tongrui Shares"	ordinary share(s) of US\$0.10 each in the share capital of Tongrui
"Turrence Limited"	a company incorporated in the B.V.I. with limited liability and an indirect wholly-owned subsidiary of the Company
"Warrantor"	Mr. Wang Fu Cai (王福才)
"Wuxi Ruinian"	Wuxi Ruinian Industry & Commerce Co., Ltd. 無錫瑞年實業有限公司, a company incorporated in the PRC

For the purpose of illustration only, RMB to HK\$ is translated at a rate of RMB1.00 to HK\$1.0344.

By Order of the Board
CK Life Sciences Int'l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 17 September 2007

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Chu Kee Hung; and the Non-executive Directors are Mr. Peter Peace Tulloch, Professor Wong Yue-chim, Richard (Independent Non-executive Director), Mrs. Kwok Eva Lee (Independent Non-executive Director) and Mr. Colin Stevens Russel (Independent Non-executive Director).

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and is not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and on the website of the Company at www.ck-lifesciences.com.